{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:13:56Z","timestamp":1790007236280,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"vor","delay-in-days":385,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.jacc.2016.11.064","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T09:01:01Z","timestamp":1487062861000},"page":"805-819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":178,"title":["Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure"],"prefix":"10.1016","volume":"69","author":[{"given":"Ratnadeep","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Poglitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haran","family":"Yogasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jissy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2016.11.064_bib1","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa020265","article-title":"Long-term trends in the incidence of and survival with heart failure","volume":"347","author":"Levy","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.11.064_bib2","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.11.064_bib3","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","article-title":"Biomarkers in heart failure","volume":"358","author":"Braunwald","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.11.064_bib4","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.11.064_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0735-1097(00)01064-0","article-title":"Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-independent hypertrophy","volume":"37","author":"Sakata","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.11.064_bib6","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.11.064_bib7","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.11.064_bib8","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1161\/hc3001.094733","article-title":"Manipulation of the renin-angiotensin system","volume":"104","author":"Givertz","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.11.064_bib9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.11.064_bib10","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.11.064_bib11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.101.8.844","article-title":"Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure","volume":"101","author":"Jorde","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.11.064_bib12","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0735-1097(01)01111-1","article-title":"Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease","volume":"37","author":"Petrie","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.11.064_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/euhj.1999.1740","article-title":"Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure","volume":"21","author":"Roig","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.11.064_bib14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2016.11.064_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/CIRCHEARTFAILURE.113.000672","article-title":"Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db\/db mice by reducing lipotoxicity and inflammation","volume":"7","author":"Mori","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2016.11.064_bib16","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/angiotensin 1-7 axis of the renin-angiotensin system in heart failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2016.11.064_bib17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.110.955369","article-title":"Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction","volume":"122","author":"Zhong","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.11.064_bib18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.108.184911","article-title":"Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart","volume":"103","author":"Mercure","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2016.11.064_bib19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jacc.2008.02.088","article-title":"Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system","volume":"52","author":"Epelman","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.11.064_bib20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacc.2016.11.064_bib21","doi-asserted-by":"crossref","first-page":"e99495","DOI":"10.1371\/journal.pone.0099495","article-title":"Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology","volume":"9","author":"Putko","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2016.11.064_bib22","unstructured":"Croghan C, Egeghy P. Methods of Dealing With Values Below the Limit of Detection Using SAS. 2003. Available at: http:\/\/analytics.ncsu.edu\/sesug\/2003\/SD08-Croghan.pdf. Accessed July 18, 2016."},{"key":"10.1016\/j.jacc.2016.11.064_bib23","doi-asserted-by":"crossref","first-page":"e00131","DOI":"10.1002\/prp2.131","article-title":"Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses","volume":"3","author":"Keizer","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jacc.2016.11.064_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2005.02.016","article-title":"Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition","volume":"106","author":"van de Wal","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2016.11.064_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.11.064_bib26","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1161\/01.CIR.96.9.3072","article-title":"Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats","volume":"96","author":"Menard","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.11.064_bib27","unstructured":"ClinicalTrials.gov. The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury. Available at: https:\/\/clinicaltrials.Gov\/ct2\/show\/nct01597635. Accessed March\u00a02016."},{"key":"10.1016\/j.jacc.2016.11.064_bib28","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2016.11.064_bib29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/1470320314568438","article-title":"Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats","volume":"16","author":"Sharp","year":"2015","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jacc.2016.11.064_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/HYPERTENSIONAHA.107.097865","article-title":"Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in\u00a0vivo","volume":"51","author":"Fuchs","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2016.11.064_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.jacc.2016.11.064_bib32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/01.HYP.31.1.362","article-title":"Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme","volume":"31","author":"Chappell","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2016.11.064_bib33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/HYPERTENSIONAHA.116.07088","article-title":"Angiotensin 1-7 is a negative modulator of aldosterone secretion in\u00a0vitro and in\u00a0vivo","volume":"68","author":"Shefer","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2016.11.064_bib34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1042\/CS20130436","article-title":"Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodeling","volume":"126","author":"McKinney","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jacc.2016.11.064_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.HYP.31.1.356","article-title":"Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system","volume":"31","author":"Iyer","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2016.11.064_bib36","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1172\/JCI39345","article-title":"Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents","volume":"120","author":"Wei","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2016.11.064_bib37","doi-asserted-by":"crossref","first-page":"22348","DOI":"10.1016\/S0021-9258(18)45712-2","article-title":"Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart","volume":"265","author":"Urata","year":"1990","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2016.11.064_bib38","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/01.RES.66.4.883","article-title":"Angiotensin II-forming pathways in normal and failing human hearts","volume":"66","author":"Urata","year":"1990","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2016.11.064_bib39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jash.2012.12.003","article-title":"Chymase mediates angiotensin-(1-12) metabolism in normal human hearts","volume":"7","author":"Ahmad","year":"2013","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.jacc.2016.11.064_bib40","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00109-014-1149-y","article-title":"Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease","volume":"92","author":"Wang","year":"2014","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.jacc.2016.11.064_bib41","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0735-1097(01)01170-6","article-title":"Activation of\u00a0the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease","volume":"37","author":"Fielitz","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.11.064_bib42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pneurobio.2011.06.006","article-title":"The role of the brain renin-angiotensin system in hypertension: implications for new treatment","volume":"95","author":"Marc","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.jacc.2016.11.064_bib43","doi-asserted-by":"crossref","first-page":"e64027","DOI":"10.1371\/journal.pone.0064027","article-title":"Proteolytic processing of angiotensin-I in human blood plasma","volume":"8","author":"Hildebrand","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716374071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716374071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T03:15:06Z","timestamp":1658632506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109716374071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0735109716374071"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2016.11.064","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2016.11.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}